These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22076476)

  • 21. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
    Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF
    Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
    Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
    Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
    Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
    Stearns V; Jegede OA; Chang VT; Skaar TC; Berenberg JL; Nand R; Shafqat A; Jacobs NL; Luginbuhl W; Gilman P; Benson AB; Goodman JR; Buchschacher GL; Henry NL; Loprinzi CL; Flynn PJ; Mitchell EP; Fisch MJ; Sparano JA; Wagner LI
    Clin Cancer Res; 2024 Jul; 30(13):2709-2718. PubMed ID: 38640040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
    Lintermans A; Laenen A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
    Ann Oncol; 2013 Feb; 24(2):350-355. PubMed ID: 23038762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
    Henry NL; Giles JT; Stearns V
    Oncology (Williston Park); 2008 Nov; 22(12):1401-8. PubMed ID: 19086600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
    Roberts K; Rickett K; Greer R; Woodward N
    Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer.
    Alhanafy AM; Labeeb A; Khalil A
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3525-3531. PubMed ID: 30583679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.
    Crew KD; Greenlee H; Capodice J; Raptis G; Brafman L; Fuentes D; Sierra A; Hershman DL
    J Clin Oncol; 2007 Sep; 25(25):3877-83. PubMed ID: 17761973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
    Henry NL; Pchejetski D; A'Hern R; Nguyen AT; Charles P; Waxman J; Li L; Storniolo AM; Hayes DF; Flockhart DA; Stearns V; Stebbing J
    Br J Cancer; 2010 Jul; 103(3):291-6. PubMed ID: 20606683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with Ruta graveolens 5CH and Rhus toxicodendron 9CH may reduce joint pain and stiffness linked to aromatase inhibitors in women with early breast cancer: results of a pilot observational study.
    Karp JC; Sanchez C; Guilbert P; Mina W; Demonceaux A; Curé H
    Homeopathy; 2016 Nov; 105(4):299-308. PubMed ID: 27914569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review.
    Andrikopoulou A; Fiste O; Liontos M; Dimopoulos MA; Zagouri F
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acupuncture for joint symptoms related to aromatase inhibitor therapy in postmenopausal women with early-stage breast cancer: a narrative review.
    Halsey EJ; Xing M; Stockley RC
    Acupunct Med; 2015 Jun; 33(3):188-95. PubMed ID: 25733539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
    Lustberg MB; Orchard TS; Reinbolt R; Andridge R; Pan X; Belury M; Cole R; Logan A; Layman R; Ramaswamy B; Wesolowski R; Berger M; Patterson E; Loprinzi C; Shapiro CL; Yee L
    Breast Cancer Res Treat; 2018 Feb; 167(3):709-718. PubMed ID: 29101597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting.
    Skafida E; Andrikopoulou A; Terpos E; Markellos C; Moustafa S; Pectasides D; Dimopoulos MA; Zagouri F; Vassilopoulos D
    Breast J; 2023; 2023():3614296. PubMed ID: 37293258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
    Castel LD; Hartmann KE; Mayer IA; Saville BR; Alvarez J; Boomershine CS; Abramson VG; Chakravarthy AB; Friedman DL; Cella DF
    Cancer; 2013 Jul; 119(13):2375-82. PubMed ID: 23575918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
    Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
    Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.
    Nyrop KA; Muss HB; Hackney B; Cleveland R; Altpeter M; Callahan LF
    J Geriatr Oncol; 2014 Apr; 5(2):148-55. PubMed ID: 24495696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Chen J; Mao JJ
    Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.